Mitchell Gary F, Dunlap Mark E, Warnica Wayne, Ducharme Anique, Arnold J Malcolm O, Tardif Jean-Claude, Solomon Scott D, Domanski Michael J, Jablonski Kathleen A, Rice Madeline M, Pfeffer Marc A
Cardiovascular Engineering, Inc., Waltham, MA 02453, USA.
Hypertension. 2007 Jun;49(6):1271-7. doi: 10.1161/HYPERTENSIONAHA.106.085738. Epub 2007 Apr 23.
The Prevention of Events with Angiotensin Converting Enzyme inhibition (PEACE) trial evaluated angiotensin-converting enzyme inhibition with trandolapril versus placebo added to conventional therapy in patients with stable coronary disease and preserved left ventricular function. The PEACE hemodynamic substudy evaluated effects of trandolapril on pulsatile hemodynamics. Hemodynamic studies were performed in 300 participants from 5 PEACE centers a median of 52 months (range, 25 to 80 months) after random assignment to trandolapril at a target dose of 4 mg per day or placebo. Central pulsatile hemodynamics and carotid-femoral pulse wave velocity were assessed by using echocardiography, tonometry of the carotid and femoral arteries, and body surface transit distances. Patients randomly assigned to trandolapril tended to be older (mean+/-SD: 64.2+/-7.9 versus 62.9+/-7.7 years; P=0.14), with a higher body mass index (28.5+/-4.0 versus 27.8+/-3.9 kg/m(2); P=0.09) and lower ejection fraction (57.1+/-8.1% versus 58.7+/-8.4%; P<0.01). At the time of the hemodynamic substudy, the trandolapril group had lower mean arterial pressure (93.1+/-10.2 versus 96.3+/-11.3 mm Hg; P<0.01) and lower carotid-femoral pulse wave velocity (geometric mean [95% CI]: 10.4 m/s [10.0 to 10.9 m/s] versus 11.2 m/s [10.7 to 11.8 m/s]; P=0.02). The difference in carotid-femoral pulse wave velocity persisted (P<0.01) in an analysis that adjusted for baseline characteristics and follow-up mean pressure. In contrast, there was no difference in aortic compliance, characteristic impedance, augmentation index, or total arterial compliance. Angiotensin-converting enzyme inhibition with trandolapril produced a modest reduction in carotid-femoral pulse wave velocity, a measure of aortic wall stiffness, beyond what would be expected from blood pressure lowering or differences in baseline characteristics alone.
血管紧张素转换酶抑制预防事件(PEACE)试验评估了在稳定型冠心病且左心室功能保留的患者中,将群多普利血管紧张素转换酶抑制与安慰剂添加到传统治疗中的效果。PEACE血流动力学亚研究评估了群多普利对搏动性血流动力学的影响。在随机分配接受目标剂量为每日4毫克的群多普利或安慰剂治疗后的中位时间52个月(范围为25至80个月),对来自5个PEACE中心的300名参与者进行了血流动力学研究。通过超声心动图、颈动脉和股动脉压力测量以及体表传输距离来评估中心搏动性血流动力学和颈动脉-股动脉脉搏波速度。随机分配到群多普利组的患者往往年龄较大(平均±标准差:64.2±7.9岁对62.9±7.7岁;P = 0.14),体重指数较高(28.5±4.0对27.8±3.9kg/m²;P = 0.09),射血分数较低(57.1±8.1%对58.7±8.4%;P<0.01)。在血流动力学亚研究时,群多普利组的平均动脉压较低(93.1±10.2对96.3±11.3mmHg;P<0.01),颈动脉-股动脉脉搏波速度较低(几何平均数[95%CI]:10.4m/s[10.0至10.9m/s]对11.2m/s[10.7至11.8m/s];P = 0.02)。在对基线特征和随访平均压力进行调整的分析中,颈动脉-股动脉脉搏波速度的差异仍然存在(P<0.01)。相比之下,主动脉顺应性、特征阻抗、增强指数或总动脉顺应性没有差异。群多普利血管紧张素转换酶抑制使颈动脉-股动脉脉搏波速度适度降低,这是一种主动脉壁僵硬度的测量指标,超出了仅由血压降低或基线特征差异所预期的范围。